Advertisement
Canada Markets closed

  • S&P/TSX

    24,162.83
    +194.33 (+0.81%)
     

  • S&P 500

    5,751.07
    +51.13 (+0.90%)
     

  • DOW

    42,352.75
    +341.15 (+0.81%)
     

  • CAD/USD

    0.7364
    -0.0004 (-0.0486%)
     

  • CRUDE OIL

    74.08
    -0.30 (-0.40%)
     

  • BTC-CAD

    86,547.16
    +2,411.32 (+2.87%)
     

  • CMC Crypto 200

    1,308.28
    0.00 (0.00%)
     

  • GOLD FUTURES

    2,665.30
    -2.50 (-0.09%)
     

  • RUSSELL 2000

    2,212.80
    +32.65 (+1.50%)
     

  • 10-Yr Bond

    3.9810
    +0.1310 (+3.40%)
     

  • NASDAQ futures

    20,224.25
    -3.00 (-0.01%)
     

  • VOLATILITY

    19.21
    -1.28 (-6.25%)
     

  • FTSE

    8,280.63
    -1.89 (-0.02%)
     

  • NIKKEI 225

    39,354.63
    +719.01 (+1.86%)
     

  • CAD/EUR

    0.6709
    0.0000 (0.00%)
     

Canadian HS Foundation Applauds Health Canada's Approval of HUMIRA(R) (Adalimumab)

Marketwired

RICHMOND HILL, ON--(Marketwired - January 06, 2016) - The Canadian Hidradenitis Suppurativa Foundation (CHSF) welcomes the decision by Health Canada to approve the biologic agent Humira® (adalimumab) for the treatment of active moderate to severe hidradenitis suppurativa (HS). Until now, there had been no approved therapies in Canada for the treatment of this debilitating, recurrent skin disease.

A chronic and systemic condition, estimated to affect between 1% to 3% of the world's population, HS often goes undiagnosed or misdiagnosed. Indeed, the journey of the Canadian patient with HS typically means many visits to multiple doctors before the condition is correctly diagnosed. Patients develop nodules or abscesses that come with an unpleasant odour and purulent drainage in areas of the body like the armpits, the groin, and the perianal region. In women, the breasts are also affected.

HS significantly impairs the quality of life of patients, many of whom stop seeking medical attention because until now it can be ineffective.

Patients who have been treated with adalimumab have experienced improvement, and it's been very encouraging for them and their families. Said one Ontario father about his daughter with long-standing HS who has begun to receive adalimumab: "She continues to show positive signs. Nobody should go for an extended period without effective treatment now that a treatment is available."

About CHSF
CHSF is dedicated to improving the daily life and quality of care for Canadians living with HS through education, research, and patient empowerment.

CHSF Objectives
CHSF has numerous objectives including awareness of HS and associated health issues, empowering HS patients to lead productive and healthy lives, creating HS research opportunities, establishing dialogue across medical specialties to enhance HS patient outcomes, and collaborating with international HS foundations to optimize research, education, and patient care.